KabiCare Patient Support Program forSTIMUFEND® (pegfilgrastim-fpgk)
STIMUFEND® (pegfilgrastim-fpgk) from Fresenius Kabi is a man-made form of granulocyte colony-stimulating factor (G-CSF). STIMUFEND is FDA approved and is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. It is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome H-ARS).
Important Safety Information